Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Carolina Schinke, Gareth Morgan, Luciano J. Costa, Natalie Callander, Don A. Stevens, Jesus G Berdeja, Brea Lipe, Sagar Lonial, Marie-Christiane Vekemans, Ravi Vij, Philippe Moreau, Paula Rodríguez-Otero, Anna Sureda Balari, Thomas Renaud, Jaszianne Tolbert, Bonnie W Lau, Brandi W Hilder, Tara J Masterson, Michela Campagna, Veronique Vreys, Christoph Heuck, Colleen Kane, Kathleen S Gray, Deeksha Vishwamitra, Indrajeet Singh, Joy Gong, Xiang Qin, Larysa Sanchez
Institutions: University of Arkansas for Medical Sciences, New York University, University of Alabama at Birmingham, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Norton Healthcare, Tennessee Oncology, University of Rochester Medicine, Winship Cancer Institute, Cliniques Universitaires Saint-Luc, Washington University in St. Louis, Universidad de Navarra, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, Janssen Research & Development (United States), Janssen (Belgium), Tisch Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405039116